Brain Research Center Den Bosch B.V.

The medical center is at the forefront of research into Dementia with Lewy Bodies (DLB), focusing on innovative treatments that target the underlying mechanisms of this complex condition. The center's work in this area is exemplified by its investigation into the efficacy of neflamapimod, a promising therapeutic agent.

• Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)
• DaTscan™ and REM sleep behavioral disorder (RBD) diagnostics

Through rigorous clinical trials, the center aims to enhance the understanding and management of DLB, offering hope for improved patient outcomes.

Specializing in Early Alzheimer's Disease, the medical center is dedicated to advancing therapeutic strategies that address the early stages of this neurodegenerative disorder. The research includes the evaluation of JNJ-63733657, an anti-tau monoclonal antibody, which is being tested for its potential to slow clinical decline.

• Integrated Alzheimer's Disease Rating Scale (iADRS)
• Anti-tau monoclonal antibody therapy

By focusing on early intervention, the center strives to mitigate the progression of Alzheimer's, thereby enhancing the quality of life for patients.

The center is also deeply involved in research on Alzheimer's Disease, particularly in patients with mild cognitive impairment (MCI) or mild dementia. The focus is on the safety and efficacy of PRI-002, a novel therapeutic agent, with an emphasis on its impact on cognitive function and safety profile.

• Clinical Dementia Rating-Sum of Boxes (CDR-SB)
• Safety and tolerability assessments

Through these studies, the center aims to contribute significantly to the development of effective treatments for Alzheimer's, addressing both cognitive and functional aspects of the disease.